An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy Adults | Zendy

Karin Levie | Zendy; Isabel LerouxRoels | Zendy; Karel Hoppenbrouwers | Zendy; AnneDiane Kervyn | Zendy; Corinne Vandermeulen | Zendy; Sheron Forgus | Zendy; G LEROUXROELS | Zendy; Sylvie Pichon | Zendy; Inca Kusters | Zendy

Open Access

An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy Adults

Author(s) -

Karin Levie,

Isabel LerouxRoels,

Karel Hoppenbrouwers,

AnneDiane Kervyn,

Corinne Vandermeulen,

Sheron Forgus,

G LEROUXROELS,

Sylvie Pichon,

Inca Kusters

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/590913

Subject(s) - adjuvant , medicine , vaccination , influenza vaccine , hemagglutinin (influenza) , hemagglutination assay , immunology , trivalent influenza vaccine , population , antibody titer , adverse effect , virology , antigen , antibody , titer , environmental health

To protect a naive global population against pandemic influenza, pandemic vaccines should be effective at low antigen doses, because of limited manufacturing capacity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research